483
Gemini Pharmaceuticals, Inc.Gemini Pharmaceuticals, Inc. – FDA 483, Jul 26, 2022
Record Details
An FDA inspection of Gemini Pharmaceuticals, Inc. in Commack, NY, revealed a significant deficiency in their manufacturing processes. The firm failed to verify that finished batches of dietary supplements met product specifications for identity, purity, strength, and composition. This was specifically noted by the absence of finished product testing for several dietary supplement products.
View Company Profile
ID · ece92446-1406-489e-aeac-8758665dd9f7
Other documents for Gemini Pharmaceuticals, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.